Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 17 for:    "Adenoma" | "Octreotide"

DOTATOC PET/CT for Imaging NET Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03583528
Recruitment Status : Recruiting
First Posted : July 11, 2018
Last Update Posted : December 25, 2018
Sponsor:
Information provided by (Responsible Party):
British Columbia Cancer Agency

Tracking Information
First Submitted Date June 8, 2018
First Posted Date July 11, 2018
Last Update Posted Date December 25, 2018
Actual Study Start Date July 11, 2018
Estimated Primary Completion Date December 31, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 28, 2018)
Sensitivity of 68Ga-DOTATOC PET/CT in the diagnosis of SSTR positive tumors. [ Time Frame: 3 years ]
Determination of sensitivity of both exams when compared with pathology reports (if available) and compared with routine imaging (CT, MRI, Octreoscan™, US) if available and will be determined by confidence intervals using an exact binominal distribution by comparing the 68Ga-DOTATOC PET/CT with 18F-FDG and conventional imaging (if available). The gold standard for the detection of lesions will be established through a combination of: 1) pathology; 2) unequivocal correlative imaging results as assessed independently by 2 physicians; 3) disease progression of specific findings upon follow-up, up to three years from baseline examination; 4) a clearly unequivocal plurimetastatic pattern confirmed by any imaging modality at any of the involved sites; 5) response of lesions on subsequent imaging following therapy.
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT03583528 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: June 28, 2018)
  • Number of participants with 68Ga-DOTATOC-related adverse events as assessed by abnormal vital sign measurement. [ Time Frame: 1 hour ]
    Vital signs (blood pressure, heart rate and pulse oximetry) will be measured at three time points (before and after injection, and 1 hour after the injection). All values that fall outside of the normal parameters will be assessed by a physician and reported as an adverse event.
  • Number of participants with self-reported 68Ga-DOTATOC-related adverse event [ Time Frame: 24 hours ]
    Patients will be contacted by phone 24 hours after the 68Ga-DOTATOC PET/CT scan to see if they experienced any adverse events. These are recorded and evaluated for severity and likelihood they are related to the study drug. All adverse events will be recorded and summarized in the final report.
  • Total number of lesions per anatomic location identified by 68Ga-DOTATOC PET/CT [ Time Frame: 3 years ]
    All lesions will be tabulated and classified by compartment (pancreas, liver, bowel, lung and mediastinum, abdomen and retroperitoneal lymph nodes, bone, other) for all imaging modalities that have been done for that subject. A total number of lesions (for all modalities) will be calculated and a proportion of lesions detected by each modality will be reported and will be compared by calculating the median and its confidence interval. This will assess the efficacy of 68Ga-DOTATOC PET/CT.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title DOTATOC PET/CT for Imaging NET Patients
Official Title Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients
Brief Summary

Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventional imaging are used to detect NETs.

This study proposes 68Gallium(68Ga)-DOTATOC positron emission tomography/computed tomography (PET/CT) is superior to current imaging techniques. The goal is to evaluate the safety and sensitivity of 68Ga-DOTATOC PET/CT at detecting NETs and other tumors with over-expression of somatostatin receptors.

Detailed Description

Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18-Fluoride-Fluorodeoxyglucose (18F-FDG). The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.

After providing informed written consent subjects will complete a medical history questionnaire.

Monitoring of adverse events There will be short-term evaluation of adverse events by comparison of vital signs before and after administration of 68Ga-DOTATOC. Twenty-four hours after 68Ga-DOTATOC administration the study coordinator will call the patient and see if they have experienced any adverse events during that time period and complete the adverse event questionnaire found in section 9.6.

Follow-up Assessments

The following information will be collected up to 3 years following the PET/CT scans:

  • Initiation of a new treatment
  • Laboratory results and pathology reports
  • Results of imaging studies
  • Final clinical diagnosis by physician and relevant clinical notes

The study is expected to take approximately 4 years for accrual.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population This will be a prospective, open-label trial in patients with suspected or proven SSTR positive tumors.
Condition
  • Neuroendocrine Tumors
  • Insulinoma
  • Gastrinoma
  • Glucagonoma
  • Vipoma
  • Pheochromocytoma
  • Paraganglioma
  • Neuroblastoma
  • Ganglioneuroma
  • Medullary Carcinoma
  • Pituitary Adenoma
  • Medulloblastoma
  • Merkel Cell Carcinoma
  • Small-cell Lung Cancer
  • Meningioma
  • Carcinoid
Intervention
  • Diagnostic Test: 68Ga-DOTATOC PET/CT

    Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection.

    Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.

    The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.

    Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.

  • Diagnostic Test: 18F-FDG PET/CT

    18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan.

    Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.

    The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.

    Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.

Study Groups/Cohorts PET/CT Diagnostic Imaging
Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18F-FDG. The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
Interventions:
  • Diagnostic Test: 68Ga-DOTATOC PET/CT
  • Diagnostic Test: 18F-FDG PET/CT
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: June 28, 2018)
400
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 31, 2026
Estimated Primary Completion Date December 31, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

All subjects:

  • World health organization performance status 0-2
  • Able to provide written informed consent/assent (or consent by guardian for subjects <19 years)
  • Patients must be able to tolerate the physical/logistical requirements of completing a PET scan including lying flat for up to 30 minutes and tolerating intravenous cannulation for injection.

Patients must require imaging for either staging or re-staging of:

  • Gastroenteropancreatic tumors (e.g. carcinoids, gastrinoma, insulinoma, glucagonoma, VIPoma, etc.), functioning and non-functioning
  • Sympathoadrenal system tumors (phaeochromocytoma, paraganglioma, neuroblastoma, ganglioneuroma)
  • Medullary thyroid carcinoma
  • Pituitary adenoma
  • Medulloblastoma
  • Merkel cell carcinoma
  • Small-cell lung cancer (mainly primary tumors)
  • Meningioma
  • Or any other NET / with potential for overexpression of SSTR

Exclusion Criteria:

  • Pregnancy
  • Patients who are medically unstable ex: acute cardiac or respiratory distress, hypotensive
  • Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70cm).
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 100 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Hayley Allan 604-877-6000 ext 2818 hayley.allan@bccancer.bc.ca
Listed Location Countries Canada
Removed Location Countries  
 
Administrative Information
NCT Number NCT03583528
Other Study ID Numbers H17-00909
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party British Columbia Cancer Agency
Study Sponsor British Columbia Cancer Agency
Collaborators Not Provided
Investigators
Principal Investigator: Francois Benard, MD BC Cancer
PRS Account British Columbia Cancer Agency
Verification Date December 2018